Alyeska Master Fund Form 4 Healthcare Merger / ANAND PAREKH ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Alyeska Investment Group, L.P.

(Last)

(First)

(Middle)

77 WEST WACKER DRIVE, 7TH FLOOR

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Healthcare Merger Corp. [ HCCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/12/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/12/2020		P		86,213	A	$10	3,086,213	D
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/12/2020		P		85,529	A	$10	3,061,717	D
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/12/2020		P		684	A	$10	24,496	D
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/12/2020		P		85,529	A	$10	3,061,717	I	Footnotes⁽²⁾⁽³⁾
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/12/2020		P		684	A	$10	24,496	I	Footnotes⁽²⁾⁽³⁾
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/12/2020		P		86,213	A	$10	3,086,213	I	Footnotes⁽²⁾⁽³⁾
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/12/2020		P		86,213	A	$10	3,086,213	I	Footnotes⁽²⁾⁽³⁾
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/12/2020		P		86,213	A	$10	3,086,213	I	Footnotes⁽²⁾⁽³⁾
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/13/2020		P		13,787	A	$10.01	3,100,000	D
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/13/2020		P		13,678	A	$10.01	3,075,395	D
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/13/2020		P		109	A	$10.01	24,605	D
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/13/2020		P		13,678	A	$10.01	3,075,395	I	Footnotes⁽²⁾⁽³⁾
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/13/2020		P		109	A	$10.01	24,605	I	Footnotes⁽²⁾⁽³⁾
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/13/2020		P		13,787	A	$10.01	3,100,000	I	Footnotes⁽²⁾⁽³⁾
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/13/2020		P		13,787	A	$10.01	3,100,000	I	Footnotes⁽²⁾⁽³⁾
Class A Common Stock⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾	10/13/2020		P		13,787	A	$10.01	3,100,000	I	Footnotes⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

Alyeska Investment Group, L.P.

(Last)

(First)

(Middle)

77 WEST WACKER DRIVE, 7TH FLOOR

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Alyeska Master Fund, L.P.

(Last)

(First)

(Middle)

77 WEST WACKER DRIVE, 7TH FLOOR

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Alyeska Master Fund 3, L.P.

(Last)

(First)

(Middle)

77 WEST WACKER DRIVE, 7TH FLOOR

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

ALYESKA FUND GP, LLC

(Last)

(First)

(Middle)

77 WEST WACKER DRIVE, 7TH FLOOR

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

ALYESKA FUND 3 GP, LLC

(Last)

(First)

(Middle)

77 WEST WACKER DRIVE, 7TH FLOOR

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

ALYESKA INVESTMENT GROUP, LLC

(Last)

(First)

(Middle)

77 WEST WACKER DRIVE, 7TH FLOOR

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

ALYESKA INVESTMENTS, LLC

(Last)

(First)

(Middle)

77 WEST WACKER DRIVE, 7TH FLOOR

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

PAREKH ANAND

(Last)

(First)

(Middle)

77 WEST WACKER DRIVE, 7TH FLOOR

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

Explanation of Responses:

1. Alyeska Investment Group, L.P. (the "Investment Manager") is the investment manager of each of Alyeska Master Fund, L.P. ("Fund 1") and Alyeska Master Fund 3, L.P. ("Fund 3" and, together with Fund 1, the "Funds"). In that capacity, the Investment Manager directs the voting and disposition of securities held by the Funds. Fund 1 is the direct owner of 3,075,395 shares of Class A Common Stock, par value $0.0001 per share ("Shares"), of Healthcare Merger Corp. Fund 3 is the direct owner of 24,605 Shares. The Investment Manager receives an asset-based fee relating to the Shares directly held by the Funds, and does not hold a pecuniary interest in such Shares.

2. (i) Alyeska Fund GP, LLC is the general partner of Fund 1 and has an indirect profits interest in the Shares directly held by Fund 1; (ii) Alyeska Fund 3 GP, LLC is the general partner of Fund 3 and has an indirect profits interest in the Shares directly held by Fund 3; (iii) Alyeska Investment Group, LLC is the sole owner of Alyeska Fund GP, LLC and Alyeska Fund 3 GP, LLC, and has an indirect profits interest in the Shares directly held by the Funds; (iv) Alyeska Investments, LLC (together with Alyeska Fund GP, LLC, Alyeska Fund 3 GP, LLC and Alyeska Investment Group, LLC, the "Upper Tier Entities") is the managing member of Alyeska Investment Group, LLC and has an indirect profits interest in the Shares directly held by the Funds; and (v) Anand Parekh is the managing member of Alyeska Investments, LLC and has an indirect profits interest in the Shares directly held by the Funds.

3. The filing of this Form 4 shall not be construed as an admission that Mr. Parekh or any Upper Tier Entity is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any Shares. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, each of Mr. Parekh and the Upper Tier Entities disclaims such beneficial ownership, except to the extent of his or its pecuniary interest.

4. On October 12, 2020, Fund 1 purchased 85,529 Shares for $10.00 per Share, and Fund 3 purchased 684 Shares for $10.00 per Share. On October 13, 2020, Fund 1 purchased 13,678 Shares for $10.01 per Share, and Fund 3 purchased 109 Shares for $10.01 per Share.

5. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16(a)-3(j) under the Exchange Act.

Remarks:

	Alyeska Investment Group, L.P., By: /s/ Jason Bragg, Chief Financial Officer	10/14/2020
	Alyeska Master Fund, L.P., By: Alyeska Fund GP, LLC, By: /s/ Jason Bragg, Chief Financial Officer	10/14/2020
	Alyeska Master Fund 3, L.P., By: Alyeska Fund 3 GP, LLC, By: /s/ Jason Bragg, Chief Financial Officer	10/14/2020
	Alyeska Fund GP, LLC, By: /s/ Jason Bragg, Chief Financial Officer	10/14/2020
	Alyeska Fund 3 GP, LLC, By: /s/ Jason Bragg, Chief Financial Officer	10/14/2020
	Alyeska Investment Group, LLC, By: /s/ Jason Bragg, Chief Financial Officer	10/14/2020
	Alyeska Investments, LLC, By: /s/ Anand Parekh, Managing Member	10/14/2020
	/s/ Anand Parekh	10/14/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Alyeska Master Fund Form 4Healthcare Merger / ANAND PAREKH ownership change